Status:
COMPLETED
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
Lead Sponsor:
Pfizer
Conditions:
Renal Dialysis
Pharmacokinetics
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3....
Detailed Description
Assess the elimination of PD-0332334 from the blood with hemodialysis
Eligibility Criteria
Inclusion
- Patients receiving regular hemodialysis
- Male or female patients 18 to 65 years
Exclusion
- Severe heart failure
- Renal transplant or renal allograft
- Illicit drug use (with the exception of prescribed sedatives)
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00730145
Start Date
September 1 2008
End Date
January 1 2009
Last Update
February 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Orlando, Florida, United States, 32809